Eric D. Shaff Seres Therapeutics, Inc. (MCRB) insider trading activity

Eric D. Shaff is CEO and President of Seres Therapeutics, Inc.. Currently has a direct ownership of 192,039 shares of MCRB, which is worth approximately $122,904. The most recent transaction as insider was on Feb 18, 2025, when has been sold 12,726 shares (Common Stock) at a price of $0.81 per share, resulting in proceeds of $10,308. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 192K

12.71% 3M change

41.91% 12M change

Total Value Held $122,904

Eric D. Shaff Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	SELL Open market or private sale	$10,308 $0.81 p/Share	12,726 Reduced 6.21%	192,039 Common Stock
Feb 15 2025	BUY Exercise of conversion of derivative security	-	34,376 Added 14.37%	204,765 Common Stock
Nov 18 2024	SELL Open market or private sale	$1,352 $0.54 p/Share	2,505 Reduced 1.45%	170,389 Common Stock
Nov 15 2024	BUY Exercise of conversion of derivative security	-	7,812 Added 4.32%	172,894 Common Stock
Oct 28 2024	SELL Open market or private sale	$6,036 $0.69 p/Share	8,748 Reduced 5.03%	165,082 Common Stock
Oct 27 2024	BUY Exercise of conversion of derivative security	-	27,837 Added 13.8%	173,830 Common Stock
Aug 16 2024	SELL Open market or private sale	$2,115 $0.84 p/Share	2,518 Reduced 1.7%	145,993 Common Stock
Aug 15 2024	BUY Exercise of conversion of derivative security	-	7,813 Added 5.0%	148,511 Common Stock
May 15 2024	SELL Open market or private sale	$2,288 $0.94 p/Share	2,435 Reduced 1.7%	140,698 Common Stock
May 15 2024	BUY Exercise of conversion of derivative security	-	7,812 Added 5.18%	143,133 Common Stock
Feb 16 2024	SELL Open market or private sale	$12,472 $1.08 p/Share	11,549 Reduced 7.86%	135,321 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	-	31,250 Added 17.54%	146,870 Common Stock
Oct 30 2023	SELL Open market or private sale	$11,545 $1.35 p/Share	8,552 Reduced 6.89%	115,620 Common Stock
Oct 27 2023	BUY Exercise of conversion of derivative security	-	27,838 Added 18.31%	124,172 Common Stock
Jul 05 2022	BUY Grant, award, or other acquisition	$200,000 $3.15 p/Share	63,492 Added 39.73%	96,334 Common Stock

Also insider at

SGTX

Sigilon Therapeutics, Inc. Healthcare

EDS

Eric D. Shaff

CEO and President

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MCRB shares.

Notify only if

Value

Insider Trading

Get notified when an Seres Therapeutics, Inc. insider buys or sells MCRB shares.

Notify only if

Operation

Value

Type

News

Receive news related to Seres Therapeutics, Inc.

Track Activities on MCRB

Account